L01DB01 · Antineoplastic and immunomodulating agents
Myocet liposomal (previously Myocet)
Indications
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Composition
- Active substance
- doxorubicin hydrochloride
- International name (INN)
- doxorubicin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Myocet liposomal (previously Myocet)
- Active substance
- doxorubicin hydrochloride
- ATC code
- L01DB01
- Therapeutic area
- Breast Neoplasms
- Marketing authorisation holder
- CHEPLAPHARM Arzneimittel GmbH